Global R&D networks

D. Jane Bower and Erica Whittaker

Industry and Innovation, 1993, vol. 1, issue 1, 50-64

Abstract: The pharmaceutical industry is of considerable interest because of the significance of R&D and marketing expenditures in securing competitive advantage. The vast costs and risks entailed in new product development have spawned an international network of cooperative alliances between large pharmaceutical companies and small biotechnology companies, creating a complex web of inter-organisa-tional linkages spanning the globe. Without formal acknowledgment, this essentially cooperative network pools the resources of cash and expertise required to bring radically new technologies, products and processes to the market, in an atmosphere of fierce global competition between the major companies. The paper examines the case of Merck and its carefully constructed AIDS programme, which balances in-house development with longterm alliances forged with smaller firms and sometimes with competitors.

Date: 1993
References: Add references at CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
http://www.tandfonline.com/doi/abs/10.1080/13662719300000005 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:taf:indinn:v:1:y:1993:i:1:p:50-64

Ordering information: This journal article can be ordered from
http://www.tandfonline.com/pricing/journal/CIAI20

DOI: 10.1080/13662719300000005

Access Statistics for this article

Industry and Innovation is currently edited by Associate Professor Mark Lorenzen

More articles in Industry and Innovation from Taylor & Francis Journals
Bibliographic data for series maintained by Chris Longhurst ().